JP Morgan Initiates Intersect ENT With Overweight

by Monica Gerson, Benzinga Staff Writer

August 18, 2014 8:45 AM | 12 seconds read | Make a Comment

Analysts at JP Morgan initiated coverage on shares of Intersect ENT

XENT

with a Overweight rating. The target price for Intersect ENT is set to $22. Intersect ENT's shares surged 1.33% to $15.25 in pre-market trading.

Posted In: Initiation Analyst Ratings JP Morgan

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.